Todos Medical Complete Valida –

NEW YORK, NY and TEL AVIV, Israel, June 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of a 27-pathogen PCR precision medicine panel for urinary tract infections ( UTI). The test is now in production and the Company is preparing to launch it commercially. Provista intends to target skilled nursing facilities, obstetricians/gynecologists and women’s health specialists as primary customers.

The main advantage of the UTI test using PCR, compared to current standard methods of cell culture testing, is that PCR is much more sensitive in identifying all major bacterial pathogens involved in UTI, compared to cell culture. which primarily identifies the most prevalent when expanding cell culture (mainly e. coli). This e. coli overrepresentation of pathogens leads to inappropriate therapy selection that results in poor patient outcomes, including prolonged and worsening symptoms. The second advantage of the PCR test over cell culture for UTI is the fast turnaround time (24h-48h) compared to cell culture (3-7 days). For caregivers in skilled nursing facilities in particular, early identification and resolution of UTIs is paramount to avoiding potentially significant side effects, including incontinence, restlessness, lethargy, falls, urinary retention, reduced mobility, decreased appetite, fever, skin flushing, back pain. , nausea and vomiting.

“Validation of a second PCR panel beyond COVID-19 establishes Provista’s profile as a precision diagnostic testing company, delivering actionable biological insights to help physicians and other medical practitioners make health care decisions. more informed treatment selection,” said Dr. Philippe Goix, Chief Commercial Officer. at Provista Diagnostics. “Our initial business plan is for the skilled nursing facilities and Ob/GYN markets, which will allow us to expand our customer base to customers who will be primary prescribers of our proprietary Videssa™ breast cancer test. We will continue to add precision medicine-based PCR testing and build disease/condition-focused panels, including in the area of ​​long COVID where we anticipate there will likely be an increased risk of breast cancer . We expect the need for precision medicine solutions that directly link diagnostic information to therapeutic selection to become increasingly important as COVID and Long COVID are likely to increase breast cancer risk, Alzheimer’s disease and other diseases related to the immune system.

About Todos Medical Ltd.

Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (TOMDF) designs life-saving diagnostic solutions for the early detection of various cancers. The company’s state-of-the-art and patented Biochemical Infrared Assays (TBIA) is a proprietary cancer screening technology using peripheral blood analysis that deploys an in-depth examination of the influence of cancer on the immune system, seeking biochemical changes in blood and plasma mononuclear cells. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos recently acquired US medical diagnostics company Provista Diagnostics, Inc. to obtain the rights to its Alpharetta, Georgia-based CLIA/CAP-certified laboratory, which currently performs COVID PCR tests and the breast cancer screening blood test. Videssa® exclusive to Provista at the commercial stage.

Todos also develops blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised cellular machinery that leads to aberrant cell cycle reentry by neurons, which then leads to apoptosis. LymPro is unique in using peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and brain neurons.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover several international suppliers of PCR test kits and related equipment and supplies, as well as antibody test kits from several manufacturers after completing validation of said test kits and supplies at its CLIA/CAP certified partner laboratory in United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting
3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.

For more information, please visit

Forward-looking statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based solely on the current expectations of management and are subject to important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties relating to the progress , timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional financing required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in the initiation of our clinical trials; changes in legislation; failure to develop and introduce new technologies, products and applications on a timely basis; lack of validation of our technology as we progress and lack of acceptance of our methods by the scientific community; the inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; cost of final product higher than expected; loss of market share and pressure on prices resulting from competition; and laboratory results that do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated by such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please see its reports filed from time to time with the United States Securities and Exchange Commission.

Company contact:
Daniel Hirsch
All medical
917-983-4229 ext. 104
[email protected]

Investor Relations contact:
Eric Ribner
LifeSci Advisors
E-mail: [email protected]